Dasatinib Accordpharma

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
30-03-2023
Ciri produk Ciri produk (SPC)
30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
30-03-2023

Bahan aktif:

dasatinib

Boleh didapati daripada:

Accord Healthcare S.L.U.

Kod ATC:

L01EA02

INN (Nama Antarabangsa):

dasatinib (anhydrous)

Kumpulan terapeutik:

Antineoplastic agents

Kawasan terapeutik:

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Tanda-tanda terapeutik:

Dasatinib Accordpharma is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Dasatinib Accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ ALL in combination with chemotherapy.

Ringkasan produk:

Revision: 1

Status kebenaran:

Withdrawn

Tarikh kebenaran:

2022-03-24

Risalah maklumat

                                60
B. PACKAGE LEAFLET
Medicinal product no longer authorised
61
PACKAGE LEAFLET: INFORMATION FOR THE USER
DASATINIB ACCORDPHARMA 20 MG FILM-COATED TABLETS
DASATINIB ACCORDPHARMA 50 MG FILM-COATED TABLETS
DASATINIB ACCORDPHARMA 70 MG FILM-COATED TABLETS
DASATINIB ACCORDPHARMA 80 MG FILM-COATED TABLETS
DASATINIB ACCORDPHARMA 100 MG FILM-COATED TABLETS
DASATINIB ACCORDPHARMA 140 MG FILM-COATED TABLETS
dasatinib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dasatinib Accordpharma is and what it is used for
2.
What you need to know before you take Dasatinib Accordpharma
3.
How to take Dasatinib Accordpharma
4.
Possible side effects
5.
How to store Dasatinib Accordpharma
6.
Contents of the pack and other information
1.
WHAT DASATINIB ACCORDPHARMA IS AND WHAT IT IS USED FOR
Dasatinib Accordpharma contains the active substance dasatinib. This
medicine is used to treat chronic
myeloid leukaemia (CML) in adults, adolescents and children at least 1
year of age. Leukaemia is a
cancer of white blood cells. These white cells usually help the body
to fight infection. In people with
CML, white cells called granulocytes start growing out of control.
Dasatinib Accordpharma inhibits
the growth of these leukaemic cells.
Dasatinib Accordpharma is also used to treat Philadelphia chromosome
positive (Ph+) acute
lymphoblastic leukaemia (ALL) in adults, adolescents and children at
least 1 year of age, and
lymphoid blast CML in adults who are not benefiting from prior
therapies. In people with ALL, white
cells called l
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Dasatinib Accordpharma 20 mg film-coated tablets
Dasatinib Accordpharma 50 mg film-coated tablets
Dasatinib Accordpharma 70 mg film-coated tablets
Dasatinib Accordpharma 80 mg film-coated tablets
Dasatinib Accordpharma 100 mg film-coated tablets
Dasatinib Accordpharma 140 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dasatinib Accordpharma 20 mg film-coated tablets
Each film-coated tablet contains 20 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 27 mg of lactose (as monohydrate).
Dasatinib Accordpharma 50 mg film-coated tablets
Each film-coated tablet contains 50 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 67.5 mg of lactose (as monohydrate).
Dasatinib Accordpharma 70 mg film-coated tablets
Each film-coated tablet contains 70 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 94.5 mg of lactose (as monohydrate).
Dasatinib Accordpharma 80 mg film-coated tablets
Each film-coated tablet contains 80 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 108 mg of lactose (as monohydrate).
Dasatinib Accordpharma 100 mg film-coated tablets
Each film-coated tablet contains 100 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 135 mg of lactose (as monohydrate).
Dasatinib Accordpharma 140 mg film-coated tablets
Each film-coated tablet contains 140 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 189 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Dasatinib Accordpharma 20 mg film-coated tablets
Medicinal product no longer authorised
3
White to off-white, round, 5.6 mm of diameter, coated tablets debossed
on one side with "DAS" and
"20" on the other side.
Dasatinib Accordpharma 50 mg film-coated tablets
White to off-white, oval, 5
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 30-03-2023
Ciri produk Ciri produk Bulgaria 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 30-03-2023
Risalah maklumat Risalah maklumat Sepanyol 30-03-2023
Ciri produk Ciri produk Sepanyol 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 30-03-2023
Risalah maklumat Risalah maklumat Czech 30-03-2023
Ciri produk Ciri produk Czech 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 30-03-2023
Risalah maklumat Risalah maklumat Denmark 30-03-2023
Ciri produk Ciri produk Denmark 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 30-03-2023
Risalah maklumat Risalah maklumat Jerman 30-03-2023
Ciri produk Ciri produk Jerman 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 30-03-2023
Risalah maklumat Risalah maklumat Estonia 30-03-2023
Ciri produk Ciri produk Estonia 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 30-03-2023
Risalah maklumat Risalah maklumat Greek 30-03-2023
Ciri produk Ciri produk Greek 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 30-03-2023
Risalah maklumat Risalah maklumat Perancis 30-03-2023
Ciri produk Ciri produk Perancis 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 30-03-2023
Risalah maklumat Risalah maklumat Itali 30-03-2023
Ciri produk Ciri produk Itali 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 30-03-2023
Risalah maklumat Risalah maklumat Latvia 30-03-2023
Ciri produk Ciri produk Latvia 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 30-03-2023
Risalah maklumat Risalah maklumat Lithuania 30-03-2023
Ciri produk Ciri produk Lithuania 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 30-03-2023
Risalah maklumat Risalah maklumat Hungary 30-03-2023
Ciri produk Ciri produk Hungary 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 30-03-2023
Risalah maklumat Risalah maklumat Malta 30-03-2023
Ciri produk Ciri produk Malta 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 30-03-2023
Risalah maklumat Risalah maklumat Belanda 30-03-2023
Ciri produk Ciri produk Belanda 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 30-03-2023
Risalah maklumat Risalah maklumat Poland 30-03-2023
Ciri produk Ciri produk Poland 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 30-03-2023
Risalah maklumat Risalah maklumat Portugis 30-03-2023
Ciri produk Ciri produk Portugis 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 30-03-2023
Risalah maklumat Risalah maklumat Romania 30-03-2023
Ciri produk Ciri produk Romania 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 30-03-2023
Risalah maklumat Risalah maklumat Slovak 30-03-2023
Ciri produk Ciri produk Slovak 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 30-03-2023
Risalah maklumat Risalah maklumat Slovenia 30-03-2023
Ciri produk Ciri produk Slovenia 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 30-03-2023
Risalah maklumat Risalah maklumat Finland 30-03-2023
Ciri produk Ciri produk Finland 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 30-03-2023
Risalah maklumat Risalah maklumat Sweden 30-03-2023
Ciri produk Ciri produk Sweden 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 30-03-2023
Risalah maklumat Risalah maklumat Norway 30-03-2023
Ciri produk Ciri produk Norway 30-03-2023
Risalah maklumat Risalah maklumat Iceland 30-03-2023
Ciri produk Ciri produk Iceland 30-03-2023
Risalah maklumat Risalah maklumat Croat 30-03-2023
Ciri produk Ciri produk Croat 30-03-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 30-03-2023

Cari amaran yang berkaitan dengan produk ini